New Zealand markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
198.61-5.72 (-2.80%)
At close: 4:00PM EDT
198.61 0.00 (0.00%)
After hours: 04:39PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 524.23B
Enterprise value 323.09B
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)34.63
Price/book (mrq)28.40
Enterprise value/revenue 333.59
Enterprise value/EBITDA 7-32.20

Trading information

Stock price history

Beta (5Y monthly) 1.21
52-week change 354.36%
S&P500 52-week change 333.64%
52-week high 3212.00
52-week low 3119.29
50-day moving average 3194.05
200-day moving average 3171.98

Share statistics

Avg vol (3-month) 3550.18k
Avg vol (10-day) 3332.6k
Shares outstanding 5118.85M
Implied shares outstanding 6N/A
Float 8118.15M
% held by insiders 10.64%
% held by institutions 196.20%
Shares short (29 Sep 2021) 44.01M
Short ratio (29 Sep 2021) 46.9
Short % of float (29 Sep 2021) 43.92%
Short % of shares outstanding (29 Sep 2021) 43.37%
Shares short (prior month 30 Aug 2021) 44.83M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin -128.96%
Operating margin (ttm)-109.35%

Management effectiveness

Return on assets (ttm)-13.65%
Return on equity (ttm)-78.71%

Income statement

Revenue (ttm)687.53M
Revenue per share (ttm)5.89
Quarterly revenue growth (yoy)112.10%
Gross profit (ttm)414.8M
EBITDA -708.47M
Net income avi to common (ttm)-886.68M
Diluted EPS (ttm)-7.59
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.9B
Total cash per share (mrq)15.99
Total debt (mrq)761.07M
Total debt/equity (mrq)89.18
Current ratio (mrq)4.91
Book value per share (mrq)7.20

Cash flow statement

Operating cash flow (ttm)-590.99M
Levered free cash flow (ttm)-791.18M